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Transforming growth factor-a regulates production of
proteoglycans by mesangial cells
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Transforming growth factor-a regulates production of proteoglycans
by mesangial cells. Accumulation of glomerular extracellular matrix is a
prominent feature of most forms of progressive glomerular disease.
Since some growth factors may play a role in extracellular matrix
production, we examined the effects of transforming growth factor-p
(TGF-p), interleukin 1, platelet derived growth factor, and tumor
necrosis factor on the production of extracellular matrix components by
cultured rat mesangial cells. In control experiments we found that
mesangial cells produced two distinct proteoglycans identified as the
small chondroitin/dermatan sulfate proteoglycans biglycan (PG I) and
decorin (PG II) by showing that their mobility on SDS-PAGE changed
upon digestion by chondroitinase ABC, and that they reacted with
antibodies raised against synthetic peptides from the core protein
sequence of human biglycan and decorin. Exposure to TGF-/3 for 48
hours stimulated an 8- to 10-fold increase in the biglycan and decorin
bands, and induced a structural change detected as a shift in electro-
phoretic mobility. TGF-3 did not demonstrably affect the production of
other matrix proteins by the mesangial cells. The other growth factors
tested had no comparable effect on the production of proteoglycans or
other extracellular matrix components by these cells. Our results show
that TGF-/3 is unique among growth factors in its regulatory effects on
mesangial cell proteoglycan production. The release or activation of
TGF-13 during glomerular injury could mediate the accumulation of
proteoglycans in the extracellular matrix and predispose the kidney to
development of glomerulosclerosis.
Pathological accumulation of extracellular matrix [1] is a
central feature of progressive glomerular disease in both ani-
mals and humans [2]. Such accumulation appears to be the
structural basis for the development of glomerulosclerosis [3, 4]
and end-stage renal disease. Extracellular matrix is a mixture of
proteoglycans, glycoproteins and collagens assembled into a
complex superstructure that promotes cell attachment [5]. In
the normal glomerulus, the mesangial cells are surrounded by
extracellular matrix, as are nearly all cells in the body. An
increase in the quantity of mesangial matrix [6], with or without
mesangial hypercellularity, is the earliest histologic finding in
many forms of glomerulonephritis [7] and in diabetic nephrop-
athy. In the latter disorder, the expansion of the mesangial
matrix correlates clinically with the development of albumin-
uria, hypertension and azotemia [8]. Cultured mesangial cells
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are known to secrete several matrix components including:
proteoglycans, fibronectin, laminin, entactin, thrombospondin
and collagen types I, III, IV and V [9—11]. However, the exact
composition and supramolecular organization of the mesangial
matrix and other extracellular matrices are unknown. Also
unknown are the factors that control the synthesis, assembly
and degradation of extracellular matrices. In a recent review of
experimental and human mesangial disorders [7] we summa-
rized the evidence that: 1) mesangial cell injury can be induced
by a variety of immunologic, toxic and hemodynamic stimuli;
and 2) despite termination of the initial stimulus there is often
progressive accumulation of mesangial matrix. Taken together,
these two facts suggest the presence of an intervening pro-
cess—a missing link—between acute injury and the progressive
buildup of glomerular extracellular matrix. We believe that the
missing link might be the activation or release of growth
factor(s) that regulate the metabolism of extracellular matrix.
Transforming growth factor-a (TGF-p) has recently been
recognized to have widespread effects on extracellular matrix
[12, 13]. TGF-13 is the most prominent member of a large gene
family of structurally-related cell regulatory proteins [13, 14].
Nearly every cell type tested has receptors for TGF-f3, includ-
ing rat kidney fibroblasts and murine glomerular mesangial,
epithelial and endothelial cells [15, 16], and TGF-/3 has been
isolated from bovine kidney [12]. TGF-/3 is termed a multifunc-
tional growth factor because it can either stimulate or inhibit
cellular proliferation, depending on the state of the cells and/or
the presence of other growth factors. In the past year, there has
been increasing evidence that TGF-f3 exerts at least some of its
diverse and multiple actions by regulating extracellular matrix
synthesis and the interaction of matrix with cells [12]. TGF-/3
stimulates synthesis of collagen, fibronectin and proteoglycans
both in vitro [17, 18] and in vivo [19], causing accumulation of
extracellular matrix. In cultured bovine cartilage, TGF-/3 in-
creased the production of proteoglycans and decreased their
catabolism in the extracellular matrix [20]. The accumulation of
extracellular matrix following TGF-p treatment may be aided
by a TGF-f3-induced decrease in levels of collagenase, metallo-
proteinase, serine protease and other enzymes that degrade
matrix proteins [21]. TGF-f3 also stimulates the expression of
extracellular matrix receptors by some cell lines [22].
In this report we show that in mesangial cell culture, TGF-/3,
but not other growth factors, regulates the production and
structure of chondroitin/dermatan sulfate proteoglycans, espe-
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cially two small proteoglycans, biglycan (PG I) and decorin (PG
II). The unique action of TGF-/3 on mesangial cell proteoglycan
production in vitro may be used as a "footprint" to identify the
involvement of TGF-J3 in glomerular disease in vivo. In a
separate study, we have obtained evidence of the TGF-f3
"footprint" in an animal model in which glomerular extracel-
lular matrix accumulation is induced by mesangial cell injury in
vivo (to be published).
Methods
Growth factors and antibodies
Bovine TGF-/31 was from Dr. D.R. Twardzik (Oncogen) and
porcine platelet TGF-f31 was obtained from R & D Systems,
Inc. (Minneapolis, Minnesota, USA). Human platelet-derived
growth factor (PDGF) and recombinant human interleukin- 1
(IL-i) a and f3 were purchased from Collaborative Research,
Inc. (Bedford, Massachusetts, USA). Recombinant human tu-
mor necrosis factor (TNF) was purchased from Amgen (Thou-
sand Oaks, California, USA). Rabbit anti-mouse fibronectin
and type IV collagen, and anti-rat laminin antibodies have been
described [23—25]. Rabbit antibodies raised against synthetic
peptides [26, 27] from the core proteins of human biglycan and
decorin were provided by Dr. L.W. Fisher, National Institutes
of Health. Polyclonal antibodies against myosin, actin, desmin,
factor VIII, cytokeratin, common leukocyte antigen and FITC-
anti-rabbit-IgG were obtained from ICN (Lisle, Illinois, USA)
and anti-thy 1.1 from Accurate Chemicals (Westbury, New
York, USA).
Cell culture
Mesangial cells were obtained from intact glomeruli of four-
to six-week-old Sprague-Dawley rats according to published
techniques [28]. The growth medium used was RPM! 1640
(Cell-Gro, Washington, D.C., USA) supplemented with 20%
heat-inactivated fetal calf serum (FCS; Hyclone, Logan, Utah,
USA), 50 U/ml penicillin, 100 g/ml streptomycin, 0.66 U/ml
insulin, and 300 mg/ml L-glutamine. Between days 15 to 20,
primary cultures were detached with a solution of 0.025%
trypsin-0.5 mri EDTA (Flow Labs, McLean, Virginia, USA)
and 2 x 106 cells were added to flasks. The cells were passed
every seven days and all experiments were performed using
cells between passages 3 and 7. Phase contrast and immunoflu-
orescence microscopy was performed by growing cells to
subconfluence on coverslips in plastic wells. The cells were
fixed with 3.7% paraformaldehyde for 10 minutes at 22°C. After
washing with phosphate buffered saline (PBS), the cells were
incubated with specific antibodies and washed and reincubated
with FITC-anti-rabbit IgG. The coverslips were mounted and
examined by phase contrast and immunofluorescence micros-
copy. This technique revealed a homogeneous population of
cells that were identified as mesangial cells according to the
following findings: 1) presence of spindle shaped morphology;
2) absence of polygonal-shaped cells; 3) bright immunofluores-
cence staining for myosin, actin, desmin, and anti-thy 1.1
antibody and negative staining for common leukocyte antigen,
cytokeratin and factor VIII. The cells also showed no morpho-
logic evidence of toxicity upon exposure to aminonucleoside of
puromycin (Sigma Chemical Co., St. Louis, Missouri, USA).
Biosynthetic radiolabeling
Equal numbers of cells were added to six-well multiwell
plates or petri dishes and allowed to grow to subconfluence.
Cultures were made serum free for 24 hours to arrest cell
proliferation. The cell layers were washed three times with
sterile PBS and serum and antibiotic free RPMI was added as a
low sulfate growth medium for 35S sulfate labeling and without
methionine (Flow Laboratories, McLean, Virginia, USA) for
35S methionine labeling. Growth factors were added to the
media for 48 hours at concentrations which showed biological
actions as determined experimentally or from the literature
[29—36]. The concentrations chosen were: TGF-/3 (25 ng/ml),
PDGF (10 U/mI), IL-i (5 U/ml) and TNF (500 U/ml). Eighteen
hours prior to termination of the experiment, S methionine
(150 Ci/ml), to label proteins or 355 sulfate (200 CI/ml), to
label proteoglycans were added to the cultures, Isotopes were
obtained from New England Nuclear (Boston, Massachusetts,
USA). The culture media were removed, phenylmethylsulfonyl
fluoride (PMSF), pepstatin and aprotinin (Sigma) were added as
protease inhibitors, and the mixtures were centrifuged for 20
minutes to remove debris. The remaining cell monolayers were
removed by washing two times with PBS followed by incuba-
tion with 300 1.d of SDS-PAGE sample buffer. The layers were
detached by agitation. Samples were electrophoresed immedi-
ately and the remainder stored at —20°C. The uptake of
3H-thymidine as a marker of cell proliferation was evaluated by
the addition of 10 1 per well of a 1 mCi/mi solution of
3H-thymidine (84 Ci/mol) diluted 1:100 with sterile PBS. The
incubations were carried out for 24 or 48 hours after which the
cells were harvested onto glass fiber filter mats using a cell
harvester (Skatron, Lierbyen, Norway). Prior to harvesting the
cells, the medium was aspirated and the cells were washed
twice with Hank's balanced salt solution. Incorporation of
3H-thymidine into cellular DNA was measured by counting the
filter mats in a liquid scintillation counter (Beckman Instru-
ments, Irvine, California, USA). In separate experiments all-
quots of cells were counted visually in a hemacytometer to
verify that the incorporation of 3H-thymidine paralleled
changes in cell numbers. Prior to harvesting, cells were evalu-
ated for evidence of cytotoxicity by phase microscopy. Cell
viability was also assessed by Tryphan blue exclusion.
Molecular identification by immunoprecipitation. Immuno-
precipitations were performed by adding 100 d of antiserum to
500 l of conditioned medium or 300 d of cell extract collected
from duplicate wells in the presence or absence or added
growth factors. In additional duplicate wells, cells were de-
tached and counted to ensure uniformity of cell number.
Preimmune serum was used in parallel control experiments.
The samples were incubated overnight at 4°C with mixing in 4
ml conical tubes precoated with bovine serum albumin (BSA).
Protein-A-Sepharose beads (Sigma) were preincubated with
fresh RPM! for 60 minutes at 22°C. To precipitate the antigen-
antibody complexes, 50 pl of suspended protein-A-Sepharose
was added to the samples, and mixed at 4°C for 120 minutes.
The samples were centrifuged for 10 minutes at 2000 x g and
the supernatant removed. The pellets were washed 10 times
with 1 ml of ice cold PBS containing 0.5 M NaCI, 0.1% SDS and
1% Triton X-100 pH 7.4. Finally, the pellets were washed with
ice cold PBS, transferred to new tubes, recentrifuged, and
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washed three times with PBS. The pellets were dissolved in 40
j.d of SDS-PAGE sample buffer containing 3% SDS and 10% /3
mercaptoethanol (Sigma) and boiled for five minutes.
Molecular identification by enzyme digestion. Enzymatic
digestion to identify proteoglycan was performed on condi-
tioned media after biosynthetic labeling. Aliquots of medium
(25 d) were mixed with 100 milliunits of chondroitinase ABC or
chondroitinase AC both in 100 mrvi Tris-HCI, pH 7.5, 10 mM
calcium acetate, 2 mg/mi BSA or 100 milliunits of heparinase 11
in 50 mM Tris-HC1, pH 7.4, 1 m calcium chloride, 5 mM
calcium acetate. All samples also received 1 mrvi PMSF, 5 mM
benzamidine, 100 p.g/ml soy bean trypsin inhibitor, 10 sg/ml
leupeptin and 10 sg/ml antipain. All materials were obtained
from Sigma. Chondroitinase-containing mixtures were incu-
bated at 37°C for 1.5 hours, and heparinase containing mixture
at 22°C for 1.5 hours. At termination samples were prepared for
SDS-PAGE.
Electrophorezic technique. Samples for SDS-PAGE were
mixed with sample buffer containing 3% SDS, 1 mrvi PMSF and
10% /3 mercaptoethanol and heated for five minutes at 100°C as
described [37]. Aliquots (20 d) were equally applied to 4 to 12%
gradient gels (Novex, Encinitas, California, USA) and run for
three hours at constant power. Gels were stained with
Coomassie Blue. Molecular size markers were from Pharmacia
(Uppsala, Sweden). Fluorography was performed by incubating
gels in Enlightning (New England Nuclear). Typical exposure
times for S methionine were one to two days and for 35S
sulfate three to five days. Fluorograms were scanned with an
ultrascan XL Enhanced Laser Densitometer (Pharmacia) to
compare and quantitate the relative intensities and mobilities of
the protein and proteoglycan bands.
Growth factor interactions
Mesangial cell cultures were prepared for biosynthetic label-
ing as described. Immediately prior to adding TGF-f3 (25 ng/ml),
PDGF (1 U/mi), IL-l (5 U/ml) or TNF (500 U/mI) were added to
the cell culture. The conditioned media were analyzed as
described.
Results
Effects ofTGF-f3 on production of extracellular matrix
components
Biosynthetic labeling of cultured mesangial cells with 355
sulfate, to label proteoglycans (Fig. 1) showed that the addition
of TGF-p induced a 10-fold increase in the production of
proteoglycans (Table 1). Under control conditions, mesangial
cells secreted into the medium two distinct small proteoglycans
that were identified as broad bands on SDS-PAGE, centered at
220 and 120 kD (Fig. 1). A third band, presumably a proteogly-
can too large to enter the gel, is seen at the top of each lane.
Exposure to TGF-/3 for 48 hours produced a clear dose-
response effect on both the quantity of each proteoglycan
produced and on the molecular weight (Fig. 2). TGF-f3 in-
creased the density of the proteoglycan band and induced a
structural change that was detected as a shift in electrophoretic
mobility. The maximal effect of TGF-f3 occurred at 25 ng/ml. At
higher concentrations there was a decrease in the action of
TGF-/3 with the effects on proteoglycan production disappear-
ing at 150 ng/ml. Examination of proteoglycan incorporation
Fig. 1. Effect of TGF-13 on synthesis of proteoglycans secreted by
mesangial cells. Cultures of rat mesangial cells were treated with
TGF-/3 for 48 hrs and metabolically labeled with 35S sulfate. Equal
volumes of conditioned media were analyzed by SDS-PAGE and
fluorography. TGF-/3 produced a 10-fold increase in the intensity of the
proteoglycan bands.
Lane
Densitometer unitsa
Proteoglycan" Proteinc
Control 3.34 2.71
TGF-p 33.76 2.38
into the extracellular matrix by extraction and parallel analysis
of the cell layer, showed a qualitatively identical TGF-/3 effect.
However, the bands were considerably less intense indicating
that the proteoglycans were mostly secreted into the medium.
Under the experimental conditions we employed, no demon-
strable effect on the pattern of protein synthesis was observed,
as revealed by 35S methionine labeling followed by SDS-PAGE
(Fig. 3) and analysis of the gels by laser densitometry (Table 1).
We compared the action of TGF-/3 (25 ng/ml) in parallel
experiments with three other growth factors, chosen because
they have been implicated in the pathogenesis of glomerular
disease. These agents were IL-l, PDGF and TNF, and they
were used at concentrations shown to produce clear biological
effects in previous studies [29—36]. A slight increase in proteo-
glycan production was seen with each of these growth factors
but none caused an induction of proteoglycans similar to TGF-/3
(Fig. 4, Table 2). An experiment with TNF identical to the one
shown in Figure 2 showed that 10 U/ml of TNF had the same
effect on proteoglycan production as 500 U/ml (data not
shown).
control TGF—$
kD
200-
lie.
Table 1. Laser densitometric analysis of conditioned media following
biosynthetic labeling with 35S sulfate (fluorogram shown in Fig. I) or
35S methionine (fluorogram shown in Fig. 3)
a Values are the means of duplicate lanes.b Values represent both the biglycan (220 kD) and decorin (120 kD)
bands. The band at the top of each lane was not included.
C Values include all of the bands in each lane.
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Fig. 2. Analysis of dose response effects of TGF-f3 on proteoglycan
production by SDS-PAGE. Cultures of rat mesangial cells were treated
with TGF-13 for 48 hrs and metabolically labeled with 35S sulfate. Equal
volumes of conditioned media were analyzed by SDS-PAGE and
fluorography. Beginning at 0.25 ng/ml (lane 2) there is an increase in
biglycan and decorin bands. At 2.5 ngtml (lane 4) a shift in electropho-
retic mobility is seen and at higher concentrations of 75 and 150 ng/ml
(lanes 7 and 8) an inhibitory effect is present. Lane 1 is control and lanes
2 to 8 represent TGF-13 at 0.25, 0.75, 2.5, 7.5, 25, 75 and 150 ng/ml,
respectively.
kD
200—
116—
Fig. 4. Effects of growth factors on proteoglycan production. Cultures
of rat mesangial cells were treated with growth factors for 48 hrs and
metabolically labeled with 35S sulfate. Equal volumes of conditioned
media were analyzed by SDS-PAGE and fluorography. TGF-/3 in-
creased two broad bands centered at 220 kD (biglycan) and 120 kD
(decorin) and induced a structural change detected as a shift in
electrophoretic mobility. PDGF, IL-I and TNF had little effect.
Table 2. Laser densitometric analysis of conditioned media following
biosynthetic labeling with 35S sulfate fluorogram (shown in Fig. 4)
Lane
Densitometnc unit?
Biglyca&' Decorin
Control 0.85 0.44
TGF-/3 6.09 4.07
IL-l 1.12 0.61
PDGF 1.01 1.47
TNF 1.23 1.48
a Values are the means of duplicate lanes.
b The biglycan band is centered at 220 kD and decorin band at 120
kD. Each proteoglycan band was analyzed separately. The band at the
top of each lane was not included.
Fig. 3. Effect of TGF-p on synthesis of proteins secreted by mesangial
cells. Cultures of rat mesangial cells were treated with TGF-13 for 48 hrs
and metabolically labeled with 35S methionine. Equal volumes of
conditioned media were analyzed by SDS-PAGE and fluorography.
TGF-/3 did not affect the general pattern of secreted proteins.
Molecular identification of proteoglycans by enzyme digestion
Digestion with glycosaminoglycan-degrading enzymes was
used to determine the type of proteoglycans that were regulated
by TGF-/3. The small proteoglycans from control and TGF-f3
treated cells were degraded by chondroitinase ABC but were
insensitive to chondroitinase AC and heparinase (Fig, 5). The
large proteoglycan(s) at the top of the gel appeared to be
partially sensitive to digestion with both chondroitinase ABC
and hepannase. These results indicate that the major proteo-
glycans produced by mesangial cells are chondroitin/dermatan
sulfate proteoglycans. In addition to identifying the glycos-
aminoglycan type, incubation of TGF-/3 conditioned medium
with chondroitinase ABC resulted in the appearance of a new 45
kD band (Fig. 5). This band is likely to represent the proteo-
glycan core proteins after removal of portions of the chon-
droitin/dermatan sulfate chains. Enzyme treatment of condi-
tioned medium from control cells did not yield a visible core
Fig. 5. Characterization of the proteoglycans regulated by TGF-f3.
Metabolically-labeled conditioned media were subjected to specific
enzyme digestion. Lanes 1-4 are control and 5-8 are media from TGF-13
treated cultures (25 ng/ml). Lanes were treated with: saline (1 and 5),
heparinase (2 and 6), chondroitinase ABC (3 and 7) and chondrointinase
AC (4 and 8). The bands were digested in lanes 3 and 7 indicating the
presence of a chondroitin/dermatan sulfate proteoglycan. Note the
appearance of a core protein band (lane 7) which has been increased by
TGF-p.
protein. This indicates that part of the regulatory action of
TGF-/3 is to stimulate new synthesis of the proteoglycan core
proteins.
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Fig. 7. Effect of PDGF on the increased proteoglycan synthesis in-
duced by TGF-f3. Equal volumes of media from cultures labeled with 35S
sulfate and treated with various growth factor combinations were
analyzed by SDS-PAGE and fluorography. (Lane I: control; Lane 2:
TGF-f3, 25 ng/ml; Lane 3: TGF-13 25 nglml + PDGF, I U/mI; lane 4:
TGF-f3 25 ng/ml + PDGF, 0.5 U/mI).
Fig. 6. Immunological identification of proteoglycans affected by
TGF-/3. Equal volumes of control (lanes I and 3) or TGF-/3 treated
(lanes 2 and 4) conditioned media were immunoprecipitated with
antiserum to synthetic peptides of the human core proteins of biglycan
(lanes 1 and 2) and decorin (lanes 3 and 4). TGF-/3 specifically increased
the biglycan and decorin bands (lanes 2 and 4) compared to control.
Immunological identification of proteoglycans by antibodies
The molecular size and type of the two proteoglycans pro-
duced by mesangial cells and regulated by TGF-p, corre-
sponded to that of two proteoglycans, biglycan (PG I) and
decorin (PG II). These proteoglycans are known to have 45 kD
core proteins, the sequences of which have been deduced from
cDNA [26, 27]. Polyclonal antibodies produced to synthetic
peptides from the sequences were used to identify the proteo-
glycans in the mesangial cell culture media. Immunoprecipita-
tion of 35S sulfate labeled conditioned media from control and
TGF-/3 treated cells followed by SDS-PAGE identified the 220
kD band as biglycan and the 120 kD band as decorin (Fig. 6).
Immunoprecipitation of conditioned media from 35S methio-
nine-labeled cells with anti-fibronectin, laminin and type IV
collagen antibodies and SDS-PAGE analysis of the immunopre-
cipitates showed no visible effect of TGF-/3 on the levels of
these proteins (data not shown).
PDGF blocks the induction of proteoglycans by TGF-f3
To study potential growth factor interactions, we exposed
mesangial cells to IL-I, PDGF and TNF before adding TGF-/3
as described above. None of these three growth factors alone
altered proteoglycan production. PDGF, however, when added
to the cells before TGF-f3, blocked the expected increase in
proteoglycan production (Fig. 7). The blocking effect did not
occur with IL-l or TNF.
Cellular effects of TGF-f3
TGF-f3 did not alter cell surface staining for laminin and type
IV collagen, but did appear to produce a subtle increase in
fibronectin (Fig. 8); however, no associated increase in fi-
bronectin production was seen in the metabolic labeling exper-
iments detailed above. Addition of TGF-f3 (25 ng/ml) to sub-
confluent mesangial cell cultures did not alter thymidine
incorporation or affect cell number compared to control (data
not shown). In contrast, both 10% FCS and PDGF (1 U/ml)
significantly increased thymidine incorporation. Visual inspec-
tion of cell morphology showed that TGF-f3 slightly and tran-
siently increased the spindle-shaped appearance of the mesan-
gial cells and caused polarization of actin fibers detected by
immunofluorescence microscopy.
Discussion
The results of our study show that, among various growth
factors, TGF-/3 increases the synthesis of proteoglycans by
mesangial cells. In contrast, the synthesis of fibronectin, lami-
nm or type IV collagen, which were the other extracellular
matrix components tested, were not substantially affected by
TGF-/3. Several lines of evidence show that the proteoglycans,
the synthesis of which was most significantly affected by
TGF-/3, are the small proteoglycans biglycan and decorin.
The identification is based on the size of the intact proteo-
glycans, the size of the core proteins and the demonstration that
the glycosaminoglycan component consists primarily of chon-
droitin/dermatan sulfate. All of these properties suggest that the
smaller proteoglycan is decorin, which has one glycosamino-
glycan chain attached to its 45 kD core protein [261, and that the
larger one is biglycan, which has two glycosaminoglycan chains
attached to its 45 kD core protein [27]. However, the most
convincing identification of these proteoglycans was obtained
with sequence-specific antibodies prepared against synthetic
peptides from the core protein sequences. The larger proteo-
glycan was preferentially immunoprecipitated with antibodies
raised against the NH2-terminal peptide of the biglycan,
whereas the smaller one reacted with antibodies raised against
the corresponding peptide from decorin. The slight precipita-
tion of biglycan with the anti-decorin seen in these experiments
is probably due to cross reactivity of the two core proteins, the
sequences of which are closely related [26, 27]. TGF-f3 also
appeared to increase the molecular mass of the proteoglycan.
This may be due to an elongation of the glycosaminoglycan
chains.
Bassols and Massague examined the effects of TGF-/3 on
various human, rodent and mink cell types including fibro-
blasts, myoblasts, preadipocytes and epithelial cells [18]. They
found that TGF-f3 induced the expression of chondroitin/der-
matan sulfate proteoglycans in varying degrees in most of these
cell lines. Although not identified with specific antibodies, the
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Fig. 8. Immunofluorescence analysis of fibronectin in mesangial cell monolayer. The cells were stained with anti-fibronectin antibody and
FITC-anti-rabbit IgG. Compared to control (A), exposure to TGF-/3 (B) resulted in increased cell surface fibronectin deposition (x630).
properties of the proteoglycans Bassols and Massague found to
be induced by TGF-13 were similar to those of the proteoglycans
affected by TGF-f3 in the glomerular mesangial cells.
The biological consequences of the stimulation of proteogly-
can production by TGF-13 are unknown, because the functions
of proteoglycans are poorly understood at present. Decorin is
known to bind fibronectin and collagen [38, 39], and it has also
been shown to have a role in the control of cell proliferation
[40]. More important in this context may be that proteoglycans
may functionally facilitate the assembly of extracellular matrix
by unidentified matrix assembly receptors [38, 41]. Such a role
is suggested by the slight increase in fibronectin deposited on
the mesangial cell surface found after exposure to TGF-f,
despite no apparent increase in fibronectin synthesis. If decorin
and biglycan can indeed increase extracellular matrix deposi-
tion, TGF-/3 could cause matrix accumulation through its effect
on proteoglycan synthesis.
Cultured mesangial cells are known to produce and respond
to growth factors [11] but the effects of TGF-f3 on matrix
synthesis is distinctive among the growth factors. Lovett and
Larsen have described the synthesis and expression of IL-i a
and p [42] by mesangial cells and IL- 1 and TNF mRNAs have
been shown to be increased in animal models of glomerulone-
phritis [43, 44]. Mesangial cells also produce PDGF [43],
platelet activating factor [45, 46] and have been shown to
proliferate in response to IL-I, PDGF, epidermal growth factor
[47], insulin growth factor I [48] and, when grown to conflu-
ence, TGF-j3 [15]. In our studies we found that IL- 1, PDGF and
TNF had little effect on proteoglycan production. Other inves-
tigators have also studied PDGF as well as epidermal growth
factor, fibroblast growth factor, insulin growth factor II, inter-
feron and dexamethasone and likewise have found little or no
effect on proteoglycan production [17]. The slight effect of IL-l
and PDGF on proteoglycan production observed in this study
may be due to the mitogenic action of these growth factors. The
effect of TNF on proteoglycan synthesis showed no relationship
to dose as did that for TGF-/3. The addition of IL-l to cultures
of human skin fibroblasts has been shown to elevate proteogly-
can core protein mRNA levels but not to increase production of
the proteoglycan [49]. Thus proteoglycan production seems to
be regulated uniquely by TGF-/3. Our finding that PDGF
blocked the effect of TGF-p suggests that other growth factors
may be involved in counter-regulating the action of TGF-f3.
We believe our results show a potentially important role for
TGF-/3 in formation of glomerular extracellular matrix mediated
by regulation of the production and structure of chondroitinl
dermatan sulfate proteoglycans by mesangial cells. These re-
sults raise the possibility that extracellular matrix production by
glomerular cells may in general be under the control of TGF-p
and that TGF-f3 may mediate the pathological increase of
extracellular matrix in progressive glomerular disease.
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